Triple Negative Breast Cancers : An Obsolete Entity?
Copyright © 2023 Elsevier Inc. All rights reserved..
Triple negative breast cancer is defined on the basis of what it is not. It has served as a useful umbrella entity for management of patients with breast cancer for the last couple of decades. However, during this period a number of novel therapies have become available. These therapies have been documented to be useful in subsets of TNBCs that can be identified on the basis of distinct biologic alterations. Herein we revisit the categorization and usage of the TNBC as an entity to assess its utility in view of the currently available therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Clinical breast cancer - 24(2024), 1 vom: 01. Jan., Seite 1-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Keskinkılıc, Merve [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Classification |
|---|
| Anmerkungen: |
Date Completed 09.01.2024 Date Revised 04.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clbc.2023.10.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365080802 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365080802 | ||
| 003 | DE-627 | ||
| 005 | 20240405233239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clbc.2023.10.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM365080802 | ||
| 035 | |a (NLM)38016912 | ||
| 035 | |a (PII)S1526-8209(23)00267-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Keskinkılıc, Merve |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Triple Negative Breast Cancers |b An Obsolete Entity? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.01.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Triple negative breast cancer is defined on the basis of what it is not. It has served as a useful umbrella entity for management of patients with breast cancer for the last couple of decades. However, during this period a number of novel therapies have become available. These therapies have been documented to be useful in subsets of TNBCs that can be identified on the basis of distinct biologic alterations. Herein we revisit the categorization and usage of the TNBC as an entity to assess its utility in view of the currently available therapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Triple negative breast cancer | |
| 650 | 4 | |a classification | |
| 650 | 4 | |a heterogeneity | |
| 650 | 4 | |a management | |
| 650 | 4 | |a subtypes | |
| 700 | 1 | |a Gökmen-Polar, Yesim |e verfasserin |4 aut | |
| 700 | 1 | |a Badve, Sunil S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical breast cancer |d 2000 |g 24(2024), 1 vom: 01. Jan., Seite 1-6 |w (DE-627)NLM11782898X |x 1938-0666 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:1-6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clbc.2023.10.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 01 |c 01 |h 1-6 | ||